Merck Cholesterol Pill
The FDA approved Merck's first-of-its-kind pill for high-risk cholesterol patients.
Summary
The FDA approved Merck’s Lipfendra, making it the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol. The pill is authorized for people with hypercholesterolemia whose artery-clogging cholesterol remains high despite statins, the standard drugs used to lower heart-attack risk. PCSK9 inhibitors block a protein that limits the liver’s removal of LDL from the blood, a treatment approach previously available only as injections. In trials cited by Merck, Lipfendra cut LDL by nearly 60%, comparable to injectable PCSK9 drugs.
Coverage Angles
Pill Breakthrough
Mostly CenterA daily oral PCSK9 drug makes injection-level LDL reduction far easier for high-risk patients. Lipfendra is a game-changing advance because it can cut bad cholesterol dramatically without shots.
Statin Alternative
Mostly CenterMerck’s pill gives patients another path when standard statins are not enough or are hard to tolerate. Cholesterol care is moving beyond reliance on statins alone toward a new oral class.
Costly Power
Mostly CenterThe new drug’s promise comes with a major affordability problem. Lipfendra may be powerful and more convenient than injections, but its high price could still limit who benefits.